Overtime nurses; Bacteria resistance; and new cancer research




Increase nursing shifts in endangered species care

Nurses pick up extra shifts for the pay or the incentive — but 50-plus hour weeks can affect their health and patient care. Evidence suggests that long working hours can harm a nurse’s physical and mental health, reduce the quality of care and lead to patient errors.

More than half of RNs and LPNs feel they are not paid enough, and many are dissatisfied with their earnings, according to Medscape’s RN/LPN Compensation Report 2022.

Errors and risks: Longer shifts resulted in more medication errors, nurses falling asleep during work hours, decreased productivity during the last 4 hours of a 12-hour shift, increased risk of errors and near misses related to reduced vigilance, impaired critical thinking, and more needlesticks. injuries, according to a study published by the American Association of Occupational Health Nurses.

Physical and mental fatigue: A shift lasting more than 8 hours can disrupt the body’s sleep-wake cycle and lead to physical and mental fatigue, leading to errors, injuries and accidents, says the US Occupational Safety and Health Administration.


UK policy could worsen antibiotic resistance

A recent UK policy allowing pharmacists to prescribe drugs for minor ailments could increase bacterial resistance to antibiotics – a growing global health problem – says one critic. The policy can lead to the overprescription of antibiotics for diseases that do not warrant them, writes Salvador Macip, MD, associate professor at the Department of Molecular and Cellular Biology at the University of Leicester in the UK and professor and researcher at the Department of Health Sciences at the Universitat Oberta de Catalunya in Barcelona, ​​​​​​Spain.

Doctors need to avoid prescribing antibiotics unless clearly needed, and patients need to complete their courses, says Macip. Additionally, they should not pressure their doctors to give them antibiotics, and they should avoid prescribing them themselves.

A little encouragement: Markets offer little incentive for drug companies to invest millions of dollars to develop new antibiotics that would only be useful for a limited time.

Possible solutions: Governments should invest more in the development of new antibiotics or offer incentives to companies to do so.


Trials begin for new cancer drugs

Six new clinical trials of promising new drugs and treatments for breast cancer have begun in recent months. The US Library of Medicine at the National Institutes of Health posted details of the trials online at clinicaltrials.gov.

“We’ve been waiting (and hoping) for a vaccine to reduce recurrence for decades,” said Kathy Miller, MD, a Medscape professor of oncology and medicine at the Indiana University School of Medicine in Indianapolis. “Cross fingers”.

New immunotherapy: Researchers will begin a randomized Phase 3 trial to test an immunotherapy called GLSI-100, developed by Greenwich LifeSciences. The trial will test the treatment in patients with HER2/node-positive breast cancer at high risk of recurrence following neoadjuvant and adjuvant post-operative therapy.

New drugs: The investigators will conduct a randomized phase 3 open-label study of giredestrant in combination with conventional therapies in patients with ER-positive, HER2-negative locally advanced/metastatic breast cancer who have received prior cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy.

Another study is ongoing, an open-label, randomized phase 3 study of gedatolisib in patients with ER-positive, HER2-negative locally advanced/metastatic breast cancer who have failed CDK 4/6 and aromatase inhibitor therapy.

For more news, follow Medscape on Facebook, TwitterInstagram and YouTube.

Leave a Comment

Your email address will not be published. Required fields are marked *